AN2 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	14.35	14.76	12.75	4.67	1.27	1.73
Research & Development	57.54	54.87	29.51	16.91	6.02	29.33
Operating Expenses	71.89	69.64	42.26	21.57	7.28	31.07
Operating Income	-71.89	-69.64	-42.26	-21.57	-7.28	-31.07
Interest & Investment Income	-	-	-	0.07	0	-
Currency Exchange Gain (Loss)	-	-	-	-0.04	-	-
Other Non Operating Income (Expenses)	5.87	4.9	1.31	-	-6.32	-2.74
Pretax Income	-66.03	-64.73	-40.96	-21.54	-13.6	-33.81
Net Income	-66.03	-64.73	-40.96	-21.54	-13.6	-33.81
Preferred Dividends & Other Adjustments	-	-	1.82	6.52	0.98	0.59
Net Income to Common	-66.03	-64.73	-42.78	-28.06	-14.58	-34.4
Shares Outstanding (Basic)	26	24	15	3	3	3
Shares Outstanding (Diluted)	26	24	15	3	3	3
Shares Change (YoY)	35.08%	53.85%	481.46%	2.71%	0.62%	-
EPS (Basic)	-2.52	-2.74	-2.79	-10.64	-5.68	-13.48
EPS (Diluted)	-2.52	-2.74	-2.79	-10.64	-5.68	-13.48
Free Cash Flow	-59.29	-53.29	-33.46	-20.48	-5.36	-14.92
Free Cash Flow Per Share	-2.26	-2.26	-2.18	-7.76	-2.09	-5.84
EBIT	-71.89	-69.64	-42.26	-21.57	-7.28	-31.07

Source: S&P Capital IQ. Standard template.